Obligation Pfitzer 4.65% ( US717081AQ68 ) en USD

Pfitzer

100 % ⇌

Etas-Unis

US717081AQ68 ( en USD )

4.65% par an ( paiement semestriel )

01/03/2018 - Obligation échue

Prospectus brochure de l'obligation Pfizer US717081AQ68 en USD 4.65%, échue

1 000 USD

300 000 000 USD

717081AQ6

Pfizer est une entreprise biopharmaceutique multinationale américaine qui développe, fabrique et commercialise des médicaments et des vaccins.

L'obligation Pfizer (US717081AQ68, CUSIP 717081AQ6) émise aux États-Unis pour un montant total de 300 000 000 USD, avec un coupon de 4,65% payable deux fois par an, échéant le 01/03/2018 et négociée par tranche minimale de 1000 USD, a atteint sa maturité et a été intégralement remboursée à 100% de sa valeur nominale en USD ; les agences de notation S&P et Moody's n'ont pas attribué de notation à ce titre.

Prospectus Supplement
424B5 1 d424b5.htm PROSPECTUS SUPPLEMENT
Table of Contents
FILED PURSUANT TO RULE 424(b)(5)
REGISTRATION NO. 333-100853
PROSPECTUS SUPPLEMENT
(To Prospectus dated November 12, 2002)

$300,000,000

Pfizer Inc.

3.30% NOTES DUE 2009
The notes will mature on March 2, 2009, will be our senior unsecured debt obligations, will not be redeemable prior to
maturity, and will not be subject to any sinking fund. Interest will be payable on the notes on March 2 and September 2 of
each year.

The underwriters propose to offer the notes from time to time for sale in negotiated transactions, or otherwise, at varying
prices to be determined at the time of each sale. The underwriters have agreed to purchase the notes from us at 99.614% of
their principal amount ($298,842,000 of proceeds to us), subject to the terms and conditions in the underwriting agreement
between the underwriters and us.

The Securities and Exchange Commission and state securities regulators have not approved or disapproved these securities,
or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to
the contrary is a criminal offense.
The underwriters expect to deliver the notes to purchasers on February 19, 2003.

Joint Book Running Managers
JPMORGAN

MORGAN STANLEY
February 13, 2003
file:////Appsrv1/ljs/Karen's%20folder/fisd/Internet%20Temp/OK/158354.htm (1 of 34)1/15/04 11:45:18 AM

Prospectus Supplement
Table of Contents

TABLE OF CONTENTS

Prospectus Supplement

Page

Disclosure Notice: Forward Looking Information

S-2
Ratio of Earnings to Fixed Charges

S-3
Use of Proceeds

S-3
Description of Notes

S-3
Underwriting

S-7
Legal Matters

S-8

Prospectus

Where You Can Find More Information

2
The Company

3
Ratio of Earnings to Fixed Charges

3
Use of Proceeds

3
Description of Debt Securities

4
Plan of Distribution

9
Validity of Debt Securities

10
Experts

11

You should rely only on the information contained or incorporated by reference in this prospectus supplement and
the accompanying prospectus. No person is authorized to give any information or to make any representations other
than those contained or incorporated by reference in this prospectus supplement or the accompanying prospectus. If
anyone provides you with different or inconsistent information, you should not rely on it. This prospectus
supplement and the accompanying prospectus is not an offer to sell or buy any securities in any jurisdiction where it
is unlawful. Neither the delivery of this prospectus supplement or the accompanying prospectus, nor any sale of
Notes made under these documents, will, under any circumstances, create any implication that there has been no
change in our affairs since the date of this prospectus supplement or the accompanying prospectus or that the
information contained or incorporated by reference is correct as of any time subsequent to the date of such
information. Our business, financial condition, results of operation and prospects may have changed since those
dates.

DISCLOSURE NOTICE: FORWARD LOOKING INFORMATION

file:////Appsrv1/ljs/Karen's%20folder/fisd/Internet%20Temp/OK/158354.htm (2 of 34)1/15/04 11:45:18 AM

Prospectus Supplement
The information contained in this prospectus supplement is accurate only as of the date hereof, and will not be updated as a
result of new information or future events or developments.
This prospectus supplement and accompanying prospectus contain or incorporate forward-looking statements within the
meaning of the securities laws about our financial results and estimates, business prospects and products in research that
involve substantial risks and uncertainties. You can identify these statements by the fact that they use words such as
"anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in
connection with any discussion of future operating or financial performance. Among the factors that could cause actual
results to differ materially are the following: the success of research and development activities and the speed with which
regulatory authorizations, pricing approvals and product launches may be achieved; competitive developments affecting our
current growth products; our ability to successfully market both new and existing products domestically and internationally;
difficulties or delays in manufacturing; trade buying patterns; our ability to meet generic and branded competition after the
loss of

S-2
file:////Appsrv1/ljs/Karen's%20folder/fisd/Internet%20Temp/OK/158354.htm (3 of 34)1/15/04 11:45:18 AM

Prospectus Supplement
Table of Contents
patent protection for our products; trends toward managed care and health care cost containment; possible U.S. legislation
affecting, among other things, pharmaceutical pricing and reimbursement, including Medicaid and Medicare; legislation or
regulations in markets outside the U.S. affecting product pricing, reimbursement or access; contingencies related to actual or
alleged environmental contamination; legal defense costs, insurance expense, settlement costs, and the risk of an adverse
decision related to product liability, patent protection and other lawsuits; our ability to protect our patents and other
intellectual property both domestically and internationally; interest rate and foreign currency exchange rate fluctuations;
governmental laws and regulations affecting domestic and foreign operations, including tax obligations; changes in
generally accepted accounting principles; any changes in business, political and economic conditions due to the threat of
future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas; ability to divest
and the timing of the divestitures of the discontinued businesses; growth in costs and expenses; changes in our product mix;
and the impact of acquisitions, divestitures, restructurings and other unusual items, including our ability to obtain the
anticipated results and synergies from our announced proposed acquisition of Pharmacia and the increased uncertainty
created by the integration of the two businesses, as well as our sale of the Tetra business, our proposed sale of the Adams
and Schick-Wilkinson Sword businesses and the timing and success of the sale of the women's health product lines. A
further list and description of these risks, uncertainties and other matters can be found in our Annual Report on Form 10-K
for the fiscal year ended December 31, 2001, and in our periodic reports on Forms 10-Q and 8-K (if any).

RATIO OF EARNINGS TO FIXED CHARGES
Our consolidated ratio of earnings to fixed charges for the nine months ended September 29, 2002 and for each of the fiscal
years ended December 31, 1997 through 2001 is set forth below. For the purpose of computing this ratio, "earnings" consist
of income from continuing operations before provision for taxes on income and minority interests and cumulative effect of a
change in accounting principle less minority interests and less undistributed earnings (losses) of unconsolidated subsidiaries
adjusted for fixed charges, excluding capitalized interest. "Fixed charges" consist of interest expense, amortization of debt
discount and expenses, capitalized interest and one-third of rental expense which we believe to be a conservative estimate of
an interest factor in our leases. It is not practicable to calculate the interest factor in a material portion of our leases. The
ratio was calculated by dividing the sum of the fixed charges into the sum of the earnings before taxes, cumulative effect of
a change in accounting principle and fixed charges, excluding capitalized interest.

(Unaudited)
Year Ended December 31

Nine Months

Ended

September 29, 2002
2001
2000
1999
1998
1997

Ratio of earnings to fixed charges

31.4

25.3
11.6
14.7 13.1 10.9

USE OF PROCEEDS
We will use the net proceeds before expenses from the sale of the Notes of approximately $298,842,000 for general
corporate purposes, including the refinancing of existing debt. We may temporarily invest funds that are not immediately
needed for these purposes in short-term marketable securities.

DESCRIPTION OF NOTES
The Notes are a series of debt securities described in the accompanying prospectus. Reference should be made to the
file:////Appsrv1/ljs/Karen's%20folder/fisd/Internet%20Temp/OK/158354.htm (4 of 34)1/15/04 11:45:18 AM

Prospectus Supplement
accompanying prospectus for a detailed summary of additional provisions of the Notes and of the indenture dated as of
January 30, 2001 between Pfizer Inc. and JPMorgan Chase Bank, formerly known as The Chase Manhattan Bank, as trustee,
under which the Notes are issued. The following description is a summary of selected portions of the indenture. It does not
restate the indenture because it, and not this description, defines your rights as a holder of the Notes.

S-3
file:////Appsrv1/ljs/Karen's%20folder/fisd/Internet%20Temp/OK/158354.htm (5 of 34)1/15/04 11:45:18 AM

Prospectus Supplement
Table of Contents
Principal, Maturity and Interest
The Notes will initially be limited to $300,000,000 aggregate principal amount. The Notes will mature on March 2, 2009.
We will issue the Notes in denominations of $1,000 and integral multiples of $1,000.
Interest on the Notes will accrue at the annual rate of 3.30%. Interest will accrue from and including February 19, 2003, and
is payable on March 2 and September 2 of each year, commencing September 2, 2003. We will make each interest payment
to the holders of record of Notes at the close of business on the next preceding February 16 or August 16.
Interest will be computed on the basis of a 360-day year comprised of twelve 30-day months. The trustee, through its
corporate trust office in the Borough of Manhattan, City of New York (in such capacity, the "paying agent") will act as our
paying agent with respect to the Notes. Payments of principal, interest and premium, if any, will be made by us through the
paying agent to DTC.
Ranking
The Notes will be unsecured general obligations of Pfizer and will rank equally with all other unsecured and unsubordinated
indebtedness of Pfizer from time to time outstanding.
Further Issues
Pfizer may, without the consent of the holders of Notes, issue additional notes having the same ranking and the same interest
rate, maturity and other terms as the Notes. Any additional notes having such similar terms, together with the Notes, will
constitute a single series of notes under the indenture. No additional notes of this series may be issued if an event of default
has occurred with respect to the Notes. Pfizer will not issue any additional notes intended to form a single series with the
Notes unless the further notes will be fungible with all notes of the same series for U.S. Federal income tax purposes.
Redemption; Sinking Fund
The Notes are not redeemable prior to maturity and will not be entitled to the benefit of a sinking fund.
Book-Entry System
The Depository Trust Company, New York, NY, will act as securities depository for the Notes. The Notes will be issued as
fully registered securities registered in the name of Cede & Co. (DTC's partnership nominee) or such other name as may be
requested by an authorized representative of DTC. One or more fully-registered Note certificates will be issued for the
Notes, in the aggregate principal amount of such issue, and will be deposited with DTC.
Beneficial interests in the Notes will be shown on, and transfers thereof will be effected only through, records maintained by
DTC and its direct and indirect participants, including Euroclear Bank S.A./N.V., as operator of the Euroclear System
("Euroclear") and Clearstream Banking, Société anonyme, Luxembourg ("Clearstream Banking"). Investors may elect to
hold interests in the Notes through any of DTC, Euroclear or Clearstream Banking, if they are participants in these systems,
or indirectly through organizations which are participants in these systems. Euroclear and Clearstream Banking hold
file:////Appsrv1/ljs/Karen's%20folder/fisd/Internet%20Temp/OK/158354.htm (6 of 34)1/15/04 11:45:18 AM

Prospectus Supplement
securities on behalf of their participants through customers' securities accounts in their respective names on the books of
their respective depositaries, which in turn hold the securities in customers' securities accounts in the depositaries' names on
the books of DTC.
DTC has informed us that DTC is:

· a limited-purpose trust company organized under the New York Banking Law;

· a "banking organization" within the meaning of the New York Banking Law;

S-4
file:////Appsrv1/ljs/Karen's%20folder/fisd/Internet%20Temp/OK/158354.htm (7 of 34)1/15/04 11:45:18 AM

Prospectus Supplement
Table of Contents

· a member of the Federal Reserve System;

· a "clearing corporation" within the meaning of the New York Uniform Commercial Code; and

· a "clearing agency" registered pursuant to the provisions of Section 17A of the Securities Exchange Act of 1934.
Euroclear and Clearstream Banking have informed us that: Euroclear and Clearstream Banking each hold securities for their
customers and facilitate the clearance and settlement of securities transactions by electronic book-entry transfer between
their respective account holders. Euroclear and Clearstream Banking provide various services including safekeeping,
administration, clearance and settlement of internationally traded securities and securities lending and borrowing. Euroclear
and Clearstream Banking also deal with domestic securities markets in several countries through established depository and
custodial relationships. Euroclear and Clearstream Banking have established an electronic bridge between their two systems
across which their respective participants may settle trades with each other.
Euroclear and Clearstream Banking customers are world-wide financial institutions including underwriters, securities
brokers and dealers, banks, trust companies and clearing corporations. Indirect access to Euroclear and Clearstream Banking
is available to other institutions which clear through or maintain a custodial relationship with an account holder of either
system.
DTC holds securities that its participants ("Direct Participants") deposit with DTC. DTC also facilitates the settlement
among Direct Participants of securities transactions, such as transfers and pledges, in deposited securities through electronic
computerized book-entry changes in Direct Participants' accounts, which eliminates the need for physical movement of
securities certificates. Direct Participants include securities brokers and dealers, banks, trust companies, clearing
corporations, and certain other organizations. DTC is owned by a number of its Direct Participants and by New York Stock
Exchange, Inc., the American Stock Exchange LLC, and the National Association of Securities Dealers, Inc. Access to the
DTC system is also available to others such as securities brokers and dealers, banks, and trust companies that clear through
or maintain a custodial relationship with a Direct Participant, either directly or indirectly ("Indirect Participants"). The rules
applicable to DTC and its Direct and Indirect Participants are on file with the Securities and Exchange Commission.
Purchases of Notes under the DTC system must be made by or through Direct Participants, which receive a credit for the
Notes on DTC's records. The ownership interest of each actual purchaser of each Note ("Beneficial Owner") is in turn to be
recorded on the Direct and Indirect Participants' records. Beneficial Owners will not receive written confirmations from
DTC of their purchase, but Beneficial Owners are expected to receive written confirmations providing details of the
transaction, as well as periodic statements of their holdings, from the Direct or Indirect Participant through which the
Beneficial Owner entered into the transaction. Transfers of ownership interests in the Notes are to be accomplished by
entries made on the books of Direct and Indirect Participants acting on behalf of Beneficial Owners. Beneficial Owners will
not receive certificates representing their ownership interests in Notes except in the event that use of the book-entry system
for the Notes is discontinued. As a result, the ability of a person having a beneficial interest in the Notes to pledge such
interest to persons or entities that do not participate in the DTC system, or to otherwise take actions with respect to such
interest, may be affected by the lack of a physical certificate evidencing such interest. In addition, the laws of some states
require that certain persons take physical delivery in definitive form of securities that they own and that security interests in
negotiable instruments can only be perfected by delivery of certificates representing the instruments. Consequently, the
ability to transfer notes evidenced by the global notes will be limited to such extent.

file:////Appsrv1/ljs/Karen's%20folder/fisd/Internet%20Temp/OK/158354.htm (8 of 34)1/15/04 11:45:18 AM

Prospectus Supplement
To facilitate subsequent transfers, all Notes deposited by Direct Participants with DTC are registered in the name of DTC's
partnership nominee, Cede & Co. or such other name as may be requested by an authorized representative of DTC. The
deposit of Notes with DTC and their registration in the name of Cede & Co. or such other nominee do not effect any change
in beneficial ownership. DTC has no knowledge of the actual Beneficial Owners of the Notes; DTC's records reflect only
the identity of the Direct Participants to whose accounts such Notes are credited, which may or may not be the Beneficial
Owners. The Direct and Indirect Participants will remain responsible for keeping account of their holdings on behalf of their
customers.

S-5
file:////Appsrv1/ljs/Karen's%20folder/fisd/Internet%20Temp/OK/158354.htm (9 of 34)1/15/04 11:45:18 AM

Prospectus Supplement
Table of Contents
Conveyance of notices and another communications by DTC to Direct Participants, by Direct Participants to Indirect
Participants, and by Direct Participants and Indirect Participants to Beneficial Owners will be governed by arrangements
among them, subject to any statutory or regulatory requirements as may be in effect from time to time.
Neither DTC nor Cede & Co. (nor such other DTC nominee) will consent or vote with respect to the Notes. Under its usual
procedures, DTC mails an Omnibus Proxy to the issuer as soon as possible after the record date. The Omnibus Proxy assigns
Cede & Co.'s consenting or voting rights to those Direct Participants to whose accounts the Notes are credited on the record
date ( identified in a listing attached to the Omnibus Proxy).
Payments of principal, interest and premium, if any, on the Notes will be made to Cede & Co., or such other nominee as
may be requested by an authorized representative of DTC. DTC's practice is to credit Direct Participants' accounts, upon
DTC's receipt of funds and corresponding detail information from us on the payable date in accordance with their respective
holdings shown on DTC's records. Payments by Participants to Beneficial Owners will be governed by standing instructions
and customary practices, as is the case with securities held for the accounts of customers in bearer form or registered in
"street name" and will be the responsibility of such Participant and not of DTC, or us, subject to any statutory or regulatory
requirements as may be in effect from time to time. Payment of redemption proceeds, distributions, and dividends to Cede &
Co. (or such other nominee as may be requested by an authorized representative of DTC) is our responsibility and
disbursement of such payments to Direct Participants will be the responsibility of DTC, and disbursement of such payments
to the Beneficial Owners will be the responsibility of Direct and Indirect Participants.
Investors electing to hold their Notes through DTC will follow the settlement practices applicable to U.S. corporate debt
obligations. The securities custody accounts of investors will be credited with their holdings on the settlement date against
payment in same-day funds within DTC effected in U.S. dollars.
Investors electing to hold their Notes through Euroclear or Clearstream Banking accounts will follow the settlement
procedures applicable to conventional eurobonds.
Secondary market sales of book-entry interests in the Notes between DTC participants will occur in the ordinary way in
accordance with DTC rules and will be settled using the procedures applicable to United States corporate debt obligations in
DTC's Settlement System. Secondary market sales of book-entry interests in the Notes held through Euroclear or
Clearstream Banking to purchasers of book-entry interests in the Notes through Euroclear or Clearstream Banking will be
conducted in accordance with the normal rules and operating procedures of Euroclear and Clearstream Banking and will be
settled using the procedures applicable to conventional eurobonds.
DTC may discontinue providing its services as securities depository with respect to the Notes at any time by giving
reasonable notice to us. Under such circumstances, in the event that a successor securities depository is not obtained, Note
certificates are required to be printed and delivered. In addition, we may decide to discontinue use of the system of book-
entry transfers through DTC (or a successor securities depository). In that event, Note certificates will be printed and
delivered. See "Description of Debt Securities--Global Securities" in the accompanying prospectus.
We will not have any responsibility or obligation to participants in the DTC system or the persons for whom they act as
nominees with respect to the accuracy of the records of DTC, its nominee or any Direct or Indirect Participant with respect
to any ownership interest in the Notes, or with respect to payments to or providing of notice for the Direct Participants, the
Indirect Participants or the beneficial owners of the Notes.
file:////Appsrv1/ljs/Karen's%20folder/fisd/Internet%20Temp/OK/158354.htm (10 of 34)1/15/04 11:45:18 AM

Document Outline

Local Disk
- #1">Prospectus Supplement